Skip to main content

Advertisement

Table 1 The expression of Oct4 and KPNA2 and their relationships with clinicopathological characteristics

From: Downregulation of KPNA2 in non-small-cell lung cancer is associated with Oct4 expression

Features No. Nuclear Oct4 immunoreactivity Nuclear KPNA2 immunoreactivity
Negative Positive (%) P Negative Positive (%) P
Age (years)        
<60 50 36(72.0) 14(28.0) 0.925 25(50.0) 25(50.0) 0.329
≥60 52 37(71.2) 15(28.8)   21(40.4) 31(59.6)  
Gender        
Male 59 42(71.2) 17(28.8) 0.920 28(47.5) 31(52.5) 0.574
Female 43 31(72.1) 12(27.9)   18(41.9) 25(58.1)  
Smoke        
Yes 52 36(69.2) 16(30.8) 0.593 22(42.3) 30(57.7) 0.563
No 50 37(74.0) 13(26.0)   24(48.0) 26(52.0)  
Histology        
Adenocarcinoma 60 41(68.3) 19(31.7) 0.387 35(58.3) 25(41.7) 0.001*
Squamous cell 42 32(72.6) 10(23.8)   11(26.2) 31(73.8)  
Carcinoma        
Differentiation        
Well 38 34(89.5) 4(10.5) 0.002* 22(57.9) 16(42.1) 0.045*
Moderate-Poor 64 39(60.9) 25(39.1)   24(37.5) 40(62.5)  
TNM stage        
I/II 55 46(83.6) 9(16.4) 0.003* 29(52.7) 26(47.3) 0.093
III/IV 47 27(57.4) 20(42.6)   17(36.2) 30(63.8)  
Angiolymphatic invasion        
No 57 44(77.2) 13(22.8) 0.156 25(43.9) 32(56.1) 0.777
Yes 45 29(64.4) 16(35.6)   21(46.7) 24(53.3)  
  1. *P < 0.05.